Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 155   

Articles published

MRK 59.06 -0.60 (-1.00%)
price chart
Merck buys rights to NewLink's experimental Ebola vaccine
(Reuters) - Merck & Co Inc (MRK.N) on Monday said it would buy worldwide commercial rights to NewLink Genetics Corp's (NLNK.
Merck & Co Inc buys rights to NewLink Genetics Corp's experimental ...  Economic Times
Canadian Ebola vaccine development taken over by Merck
Related articles »  
Merck & Co., Inc. Tops Earnings, Misses Revenue Estimates
Merck & Co., Inc. (NYSE:MKR) released the earnings results from its third quarter this morning before opening bell, posting adjusted earnings of 90 cents per share on $10.56 billion in revenue.
Related articles »  
Anti-PD-1 Drug Keytruda Gives Merck & Co. (MRK) Reason To Rejoice Again
Merck & Co., Inc. (NYSE:MRK) has announced positive Phase II trial results for its anti-PD-1 therapy Keytruda (pembrolizumab).
Medical Breakthroughs On The Horizon For Merck (MRK)
Merck (MRK) is a global health care company that includes prescription medicines; vaccines, biologic therapies, animal health and consumer care products.
Pfizer Inc. (NYSE:PFE) May Cut R&D Costs as Merck & Co., Inc. (NYSE:MRK ...
Shares of Pfizer Inc. (NYSE:PFE) [Detail Analytic Report] slightly down in early trading session as it might have sliced they should had on R&D expenses, according to market experts.
Related articles »  
Merck & Co., Inc. (NYSE:MRK) Reports Results from Hepatitis C Treatment
Merck & Co., Inc. (NYSE:MRK) reported Tuesday promising results from a multi-arm Phase 2 clinical trial evaluating grazoprevir/elbasvir, a product to treat the chronic hepatitis C virus genotype 1 in treatment-naive and previously-treated patients.
Merck Reports Interim Data on Hepatitis C Virus Drug  Yahoo News
Related articles »  
NewLink Genetics, Merck & Co. (MRK) In Talks To Scale Up Ebola Vaccine ...
NewLink Genetics Corp (NASDAQ:NLNK) and Merck & Co., Inc. (NYSE:MRK) are rumored to have come to the table for talks to research possible ways to increase the production of NewLink's experimental Ebola vaccine.
NewLink in Talks With Merck on Producing Ebola Vaccine  Bloomberg
Related articles »  
Interesting January 2017 Stock Options for Merck & Co.
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co Merck & Co., Inc (NYSE: MRK). So this week we highlight one interesting put contract, and one interesting call contract ...
Related articles »  
Stock Runners: Merck & Co. Inc. (NYSE:MRK), The Home Depot (NYSE:HD ...
Merck & Co. Inc. (NYSE:MRK) on 17 November announced positive results from a pivotal phase II study (KEYNOTE-002) on its anti-PD-1 therapy, Keytruda (pembrolizumab).
Related articles »  
Merck & Co.'s (MRK) Cholesterol Drug Vytorin Reduced Risk Of Heart Attacks ...
Merck & Co., Inc.'s (NYSE:MRK) cholesterol drug Vytorin was successful in meeting the primary endpoint of lowering the risks of second heart attacks in patients already undergoing an aggressive treatment, results from a study of the drug show.